Lyell Immunopharma, Inc.

Informe acción NasdaqGS:LYEL

Capitalización de mercado: US$286.7m

Salud financiera de hoja de balance de Lyell Immunopharma

Salud financiera controles de criterios 6/6

Lyell Immunopharma tiene un patrimonio de los accionistas total de $566.5M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $654.1M y $87.6M respectivamente.

Información clave

0%

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$491.12m
PatrimonioUS$566.50m
Total pasivoUS$87.64m
Activos totalesUS$654.14m

Actualizaciones recientes sobre salud financiera

Recent updates

Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth

Oct 25

Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts

Apr 16

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Feb 23
Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Nov 09
Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Analysts' Revenue Estimates For Lyell Immunopharma, Inc. (NASDAQ:LYEL) Are Surging Higher

Aug 29
Analysts' Revenue Estimates For Lyell Immunopharma, Inc. (NASDAQ:LYEL) Are Surging Higher

We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth

Aug 11
We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth

Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth Plans

Dec 15
Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth Plans

Lyell Immunopharma gets FDA nod to start phase 1 trial of its cancer therapy LYL845

Oct 06

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Sep 12
Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

News Flash: Analysts Just Made A Huge Upgrade To Their Lyell Immunopharma, Inc. (NASDAQ:LYEL) Forecasts

Aug 08
News Flash: Analysts Just Made A Huge Upgrade To Their Lyell Immunopharma, Inc. (NASDAQ:LYEL) Forecasts

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Apr 29
Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth

Dec 31
We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn Situation

Sep 17
Here's Why We're Not Too Worried About Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn Situation

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($499.8M) de LYEL superan a sus pasivos a corto plazo ($30.9M).

Pasivo a largo plazo: Los activos a corto plazo de LYEL ($499.8M) superan a sus pasivos a largo plazo ($56.8M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: LYEL está libre de deudas.

Reducción de la deuda: LYEL no ha tenido ninguna deuda en los últimos 5 años.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: LYEL tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: LYEL dispone de suficiente cash runway para 2.6 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 5.8% cada año.


Descubre empresas con salud financiera